3-rx.comCustomer Support
3-rx.com
   
HomeAbout UsFAQContactHelp
News Center
Health Centers
Medical Encyclopedia
Drugs & Medications
Diseases & Conditions
Medical Symptoms
Med. Tests & Exams
Surgery & Procedures
Injuries & Wounds
Diet & Nutrition
Special Topics



\"$alt_text\"');"); } else { echo"\"$alt_text\""; } ?>


Join our Mailing List





Syndicate

You are here : 3-RX.com > Home > Cancer - Prostate Cancer -

Racial differences again seen in prostate cancer

Cancer • • Prostate CancerAug 07, 08

Black men with prostate cancer, compared with their White counterparts, have a poorer prognosis that is not fully explained by other “co-morbid” illnesses, or by different screening rates or access to healthcare, researchers from the UK report.

The finding stems from a systematic review and pooled analysis of 48 published studies that reported Black-White differences in prostate cancer prognosis.

“Some of the differences in prostate cancer mortality may reflect less aggressive management amongst Black men, particularly in older cohorts,” Dr. Yoav Ben-Shlomo from the University of Bristol and colleagues suggest in a report in the International Journal of Cancer.

“However, even in the presence of optimal care of equal standard for both Black and White men, there may remain differences due to underlying biological factors,” they note.

In their analyses, Ben-Shlomo and colleagues found that Black men had worse overall survival that was not due to the presence of other illnesses.

Deaths due specifically to prostate cancer and recurrence of prostate cancer, as indicated by rising levels of the prostate cancer-specific blood protein PSA, showed a persistent elevated risk of around 10 percent to 25 percent for Black men, they report.

The researchers suggest that either management differences for early “organ-confined” prostate cancer and/or biological differences “may be behind Black-White differences in prostate cancer prognosis.”

SOURCE: International Journal of Cancer, July 15, 2008.



Print Version
Tell-a-Friend
comments powered by Disqus

RELATED ARTICLES:
  New biomarkers may influence drug design and alternative treatments of cancer, study shows
  Metabolic profiles distinguish early stage ovarian cancer with unprecedented accuracy
  Moffitt researchers develop first genetic test to predict tumor sensitivity to radiation therapy
  New drug for neuroblastoma shows promise in phase I study
  Experimental treatment sends deadly leukemia into remission
  Study could reduce unnecessary cancer screening
  UA researchers discover component of cinnamon prevents colorectal cancer in mice
  Profiling approach to enable right lung cancer treatment match
  Fat grafting technique improves results of breast augmentation
  Germline TP53 mutations in patients with early-onset colorectal cancer
  Clinical trial suggests combination therapy is best for low-grade brain tumors
  UW research shows sensor technology may help improve accuracy of clinical breast exams

 












Home | About Us | FAQ | Contact | Advertising Policy | Privacy Policy | Bookmark Site